Why partner with us? At Cambridge Cognition we are accelerating clinical research through cognitive assessments, quality assurance and data integrity. Read more about our product offering and how we continue to drive progress within CNS research. https://lnkd.in/eMzP-SpE
Cambridge Cognition
Biotechnology Research
Bottisham, England 6,248 followers
Leaders in digital assessment
About us
Cambridge Cognition Plc (AIM: COG) is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. Our software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries. Our digital health products have been used for over 30 years in thousands of academic and industry clinical trials by the world's leading pharmaceutical and biotech companies, academic institutions and health organisations.
- Website
-
http://www.cambridgecognition.com
External link for Cambridge Cognition
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Bottisham, England
- Type
- Public Company
- Founded
- 2002
- Specialties
- cognitive assessments, dementia, CANTAB, mental health, digital health, technology, software, Alzheimer's disease, brain health, and cognition
Locations
-
Primary
Get directions
Tunbridge Court
Bottisham, England CB25 9, GB
-
Get directions
1 Broadway
Cambridge, Massachusetts, US
-
Get directions
5 Libertas Road
Unit 9 Somerset Business Park
Bryanston, Gauteng 2191, ZA
Employees at Cambridge Cognition
Updates
-
Tomorrow at #aaic24, join Bill Simpson at 9am in 120 ABC to find out more about our research into digital phenotyping of speech and language. Pop by Booth 1336 if you'd like to discuss how this can support your research.
-
-
We're counting down the days to #AAIC24. Our scientists, Bill Simpson and Michael Spilka, will be available to discuss how to get the most from technologies to accelerate your #alzheimers research, and our Business Development team can show you what the technology can do! Connect with Deanna Friedrich, Dan Serrano and Charlie Mains to find out more.
-
-
We're looking forward to meeting you at AAIC on Sunday! We'll be presenting our latest research and showcasing how our platform can accelerate your Alzheimer's Disease research using cognitive assessments (including speech and actigraphy), eCOA solutions and automated quality assurance. Email enquiries@camcog.com for more information.
-
-
Our combined voice and touchscreen tests will deliver gold-standard, multimodal brain health assessments sensitive to the earliest signs of neurodegeneration in the Bio-Hermes 2 trial, providing open-ended language assessments supported by a machine-learning analytics pipeline with proven effectiveness in detecting Alzheimer's disease. Find out more: https://lnkd.in/geGDBKaH
-
-
Doesn't get much better than that. Here's to transforming healthcare and improving lives, 10 years at a time. 💪🚀 Find out more here: www.cambridgecognition.com #Excellence
-
-
Live tomorrow at 9:20am, Bill Simpson, our Head of Clinical Science will be presenting a case study at the Digital Biomarkers in Clinical Trails Summit at Roche, Basel. Can't make it but want to learn more about speech biomarkers in CNS clinical trials? Email enquiries@camcog.com
-
-
Here's to always delivering top-notch service and continuously exceeding customer expectations.🚀 Find out more here: www.cambridgecognition.com #CSAT #CustomerService
-
-
Join us next week at the Digital Biomarkers in Clinical Trials Summit at Roche, Basel where our Head of Clinical Science will be presenting a case study on the development and validation of speech biomarkers. Register now: https://lnkd.in/eV9WW2HD